Finding 392502 (2022-002)

Material Weakness
Requirement
M
Questioned Costs
-
Year
2022
Accepted
2024-04-08
Audit: 302833
Organization: Rtog Foundation, Inc. (PA)

AI Summary

  • Core Issue: The Foundation lacks formal documentation and policies for monitoring subrecipient activities, violating 2 CFR section 200.332.
  • Impacted Requirements: Failure to monitor could lead to noncompliance with federal regulations and subaward terms.
  • Recommended Follow-Up: Establish written policies for subrecipient monitoring, ensuring compliance with all required elements of 2 CFR 200.332.

Finding Text

Finding 2022-002: Department of Health and Human Services – Research & Development Cluster – ALN #93.394, #93.395, and #93.399 – Subrecipient Monitoring Criteria: 2 CFR section 200.332 requires pass-through entities to evaluate each subrecipient’s risk of noncompliance, monitor the activities of the subrecipient as necessary to ensure that the subaward is used for authorized purposes and is in compliance with federal statutes, regulations, and the terms and conditions of the subaward, and verify that every subrecipient is audited as required by Subpart F, as necessary. Statement of Condition: No formal documentation existed to indicate that the Foundation performed the required monitoring of its subrecipient’s activity and no written policy exists to establish procedures to document the monitoring of the subrecipient. Cause: The Foundation does not have employees and is operated by a volunteer Board of Directors. Additionally, no formal policies were written to establish procedures to document monitoring of subrecipients. Effect: A failure to monitor a subrecipient's compliance with relevant federal requirements could result in noncompliance with the terms and conditions of the subawards. Subrecipient monitoring was ineffective. Questioned Costs: None. Identification as a Repeat Finding: Not a repeat finding. Recommendation: We recommend that the Foundation establish written policies to document the monitoring of its subrecipient by an individual independent of the subrecipient. This policy should address all required elements of 2 CFR 200.332. Views of Responsible Officials: Management agrees with finding; see separate corrective action plan.

Categories

Subrecipient Monitoring

Other Findings in this Audit

  • 392492 2022-001
    Significant Deficiency
  • 392493 2022-001
    Significant Deficiency
  • 392494 2022-001
    Significant Deficiency
  • 392495 2022-001
    Significant Deficiency
  • 392496 2022-001
    Significant Deficiency
  • 392497 2022-001
    Significant Deficiency
  • 392498 2022-001
    Significant Deficiency
  • 392499 2022-002
    Material Weakness
  • 392500 2022-002
    Material Weakness
  • 392501 2022-002
    Material Weakness
  • 392503 2022-002
    Material Weakness
  • 392504 2022-002
    Material Weakness
  • 392505 2022-002
    Material Weakness
  • 968934 2022-001
    Significant Deficiency
  • 968935 2022-001
    Significant Deficiency
  • 968936 2022-001
    Significant Deficiency
  • 968937 2022-001
    Significant Deficiency
  • 968938 2022-001
    Significant Deficiency
  • 968939 2022-001
    Significant Deficiency
  • 968940 2022-001
    Significant Deficiency
  • 968941 2022-002
    Material Weakness
  • 968942 2022-002
    Material Weakness
  • 968943 2022-002
    Material Weakness
  • 968944 2022-002
    Material Weakness
  • 968945 2022-002
    Material Weakness
  • 968946 2022-002
    Material Weakness
  • 968947 2022-002
    Material Weakness

Programs in Audit

ALN Program Name Expenditures
93.395 Cancer Treatment Research $1.88M
93.399 Cancer Control $618,671
93.394 Cancer Detection and Diagnosis Research $11,972